Cipla Ltd.

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023, Cipla has informed that it enclosed a disclosure in Annexure-1 and a press release dated 22nd May 2024 titled ‘Cipla receives final approval for the generic version of Somatuline® Depot (lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL’.

The above information is a part of company’s filings submitted to BSE.